Atea Pharmaceuticals (NASDAQ: AVIR) announced it has completed patient enrollment in its C-FORWARD Phase 3 clinical trial evaluating a fixed-dose ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE